Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans

@article{Hinderling2005PharmacokineticsOT,
  title={Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans},
  author={P. Hinderling and E. R. Garrett},
  journal={Journal of Pharmacokinetics and Biopharmaceutics},
  year={2005},
  volume={4},
  pages={199-230}
}
  • P. Hinderling, E. R. Garrett
  • Published 2005
  • Medicine, Chemistry
  • Journal of Pharmacokinetics and Biopharmaceutics
  • The pharmacokinetics of the antiarrhythmic disopyramide, 4-diisopropylamino-2-phenyl-2-(2-pyridyl)butyramide phosphate, and its monodealkylated metabolite were investigated in seven volunteers after intravenous (1 and 2 mg/kg) and oral (3 and 6 mg/kg) administration. Unchanged drug (52%) and the monodealkylated metabolite (25%) were renally excreted on intravenous administration. The pharmacokinetics of disopyramide were first order and dose independent only when referenced to the drug not… CONTINUE READING

    Topics from this paper.

    Kinetics of disopyramide in decreased hepatic function
    Bioavailability of disopyramide in normal volunteers using unbound concentration
    2
    Role of concentration-dependent plasma protein binding in disopyramide disposition
    32
    Disopyramideand Its MonoN-deal kylated Metabolite
    • LiquidChromatographic Analysisof, J. Lima
    • 2004

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 39 REFERENCES
    Species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate.
    12
    Disopyramide phosphate: Clinical efficacy of a new oral antiarrhythmie drug
    36
    Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite.
    33
    Influence of first-pass effect on availability of drugs on oral administration.
    142
    Influence of route of administration on drug availability.
    150
    Route of administration and drug metabolism.
    15
    Effects of protein bindings of drugs on areas under plasma concentration--time curves.
    4